STRN4 and adenocarcinoma: In conclusion, we identified Treprostinil and 10‐HCPT as promising DHHC9 inhibitors, capable of suppressing adenocarcinoma cell migration by blocking the palmitoylation of DHHC9 and its substrate STRN4.